Introduction
============

With sedentary lifestyles and imbalanced dietary choices, the obese population is increasing in Japan.[@b1-tcrm-11-371] This growing obesity epidemic increases the risk of mortality and morbidity, which is a major public health concern in Japan. In 2012, the Japan Society of Ningen Dock reported that liver dysfunction is the single most frequent abnormal finding in multiphase health screening.[@b2-tcrm-11-371] The main cause of liver dysfunction is considered to be nonalcoholic fatty liver disease (NAFLD), a condition characterized by excessive accumulation of hepatocellular lipids, ie, steatosis, and is strongly associated with obesity.[@b3-tcrm-11-371]

Other than dietary and exercise therapies, no effective treatment for NAFLD has been identified.[@b4-tcrm-11-371] Although the importance of exercise in NAFLD is widely recognized, people often have difficulty finding sufficient time to exercise. Meanwhile, obese patients often find exercise difficult to perform because of the excess weight exerted on the knee and hip joints.

To improve the quality of life of obese subjects with NAFLD, it is important to maintain their skeletal muscle mass through moderate exercise.[@b5-tcrm-11-371] Skeletal muscles are not merely organs of locomotion; as metabolic organs, they are also involved in regulation of glucose metabolism.[@b6-tcrm-11-371] In particular, in cases where the patient is middle-aged or older, finding ways to prevent age-related muscle atrophy and decreased muscle strength while improving metabolic function is important for preventing the spread of liver lesions. Under such circumstances, it is necessary for those with NAFLD to practice an exercise training method that is simple, safe, and effective.

Hybrid training (HYB) was developed to prevent muscle atrophy in astronauts spending long periods in space stations.[@b7-tcrm-11-371] In the present study, we used HYB as a form of exercise therapy for NAFLD. HYB is a type of skeletal muscle training that combines spontaneous muscular constriction with electrical constriction in response to electrical stimulation. The contractile force generated by applying an electrical stimulus to the antagonist opposing the agonist muscle is utilized as motion resistance. These principles can be applied to obtain a strength training effect accompanying articular movement. In addition, HYB has a greater training effect than conventional electrical training methods because it uses centrifugal contraction induced by electrical stimulation, which makes it possible to utilize a greater exercise load with the same amount of electrical stimulation. The intensity of the electrical stimulation can be adjusted, making it possible to minimize the pain and discomfort of the electrical stimulus.[@b8-tcrm-11-371]--[@b10-tcrm-11-371] HYB can be performed over a short period of time in a seated position, making it suitable for patients who are severely obese and those who have arthritis of the lumbar spine or knee.

Following on from recent studies,[@b11-tcrm-11-371],[@b12-tcrm-11-371] we conducted a pilot study involving middle-aged obese women with NAFLD who underwent HYB for 24 weeks to evaluate its efficacy from the standpoints of skeletal muscle mass, strength and ectopic adipose, body composition, glucose and lipid metabolism, liver dysfunction, and improvement in inflammatory and oxidative stress markers.

Materials and methods
=====================

Subjects and study design
-------------------------

This study was conducted as a pilot to investigate the therapeutic efficacy of HYB for the lower extremities in middle-aged obese women with NAFLD. [Figure 1](#f1-tcrm-11-371){ref-type="fig"} depicts the workflow of enrollment of study subjects. Between April 2011 and December 2014, 55 patients with NAFLD presented to an outpatient department specializing in lifestyle-related liver diseases at the Tsukuba University Hospital. None of the patients consumed excess alcohol (\>20 g/day), had another cause of liver disease or a psychiatric illness, or were taking antidiabetic or weight loss agents. Each patient received lifestyle counseling regarding diet and physical activity for NAFLD according to the guidelines of the American Gastroenterological Association.[@b13-tcrm-11-371] The counseling was conducted by a registered dietitian and a medical doctor specializing in nutrition. Twelve weeks after the counseling, 40 patients showed either a decrease or no change in serum alanine aminotransferase (ALT) levels and liver fat deposition evaluated by abdominal ultrasonography.[@b14-tcrm-11-371] The remaining 15 patients (mean age 61.2±6.0 years) showed an increase in serum ALT levels or liver fat deposition and were enrolled in this study. These women with NAFLD visited the rehabilitation division of Tsukuba University Hospital twice a week and performed HYB. The diagnosis of NAFLD was based on elevated serum ALT levels and the presence of at least two of three abnormal findings on abdominal ultrasonography, ie, diffusely increased liver echogenicity ("bright") that was greater than for the kidney, vascular blurring, or deep attenuation of the ultrasound signal according to the diagnostic guidelines for NAFLD in the Asia-Pacific region.[@b15-tcrm-11-371]

Written informed consent was obtained from each patient. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected in prior approval by the ethics committee of the University of Tsukuba Faculty of Medicine.

Hybrid training
---------------

HYB was performed in a sitting position without the feet touching the floor, as previously described.[@b9-tcrm-11-371],[@b10-tcrm-11-371] Briefly, the hamstrings were electrically stimulated when the knee was voluntarily extended ([Figure 2A](#f2-tcrm-11-371){ref-type="fig"}), whereas the quadriceps were electrically stimulated when the knee was voluntarily bent and flexed ([Figure 2B](#f2-tcrm-11-371){ref-type="fig"}).

The HYB lasted for 19 minutes per session, and sessions were scheduled twice a week for 24 weeks (a total of 48 sessions). Each session consisted of ten sets of ten reciprocal 3-second knee flexion and extension contractions. The sets were separated by a one-minute rest interval. The electrical stimulation intensity was set at a level of 20--25 consecutive knee flexions and extensions. The mean stimulating voltages were 29.5±6.5 V and 31.4±6.7 V for the quadriceps and hamstring muscles, respectively. This voltage level does not cause pain. The joint motion sensor (Mutoh Engineering Inc., Tokyo, Japan) triggered stimulation of the antagonist muscle once it sensed initiation of volitional contraction of the agonist.

Assessment of total energy intake
---------------------------------

For assessment of total daily energy intake, the subjects recorded their food intake for 3 consecutive days at both baseline and week 24 under the supervision of a professional dietitian. The dietitian estimated these using Excel Eiyo-Kun version 4 software (Kenpakusya, Tokyo, Japan).

Body weight and composition
---------------------------

Body weight and composition were measured using an InBody720 (Biospace Japan Inc., Tokyo, Japan). Standing height was measured by a wall-mounted stadiometer (Muratec-KDS Co., Kyoto, Japan) and used to calculate body mass index (kg/m^2^).

Measurement of muscle strength
------------------------------

Maximal strength of isometric contraction of knee flexion and extension at an angle of 90° in a seated position was measured using a dynamometer (Biodex III, Biodex Medical Systems Inc., Shirley, NY, USA). The peak torque (Nm) of the records of three consecutive trials was considered as the maximal strength. Each isometric contraction was held for 3 seconds. The results were normalized by body weight (kg).

Ultrasonography
---------------

An ultrasound scanner (SSD-5500, Aloka Co. Ltd., Tokyo, Japan) was used to evaluate steatosis of the liver. The grade of liver steatosis was determined by a clinical radiologist according to the criteria of Saadeh et al.[@b14-tcrm-11-371] The radiologist was blinded to treatment allocation. The films were scored in random order without any clinical information.

Magnetic resonance spectroscopy
-------------------------------

A 3-Tesla magnetic resonance device (Achieva, Philips Electronics Japan, Ltd., Tokyo, Japan) equipped with a 6-channel Torso coil was used for this study. The excitation method was spin echo point-resolved spatially localized spectroscopy, and data were acquired by the single voxel method. The data obtained were analyzed with LCModel software (LA Systems Inc., Tokyo, Japan).[@b16-tcrm-11-371]

Laboratory determinations
-------------------------

Blood samples were drawn from the median cubital vein at baseline and at week 24 following a period of no training for 48 hours and fasting for 12 hours. Triglyceride and high-density lipoprotein cholesterol levels were analyzed by an enzyme method, aspartate aminotransferase (AST), ALT, and gamma-glutamyl transpeptidase (γ-GT) levels by the transferable method of the Japan Society of Clinical Chemistry, fasting plasma insulin level by a chemiluminescent immunoassay method, high-sensitivity C-reactive protein by a fixed time assay method, fasting plasma glucose by a glucose-6-phosphate dehydrogenase method, and glycated hemoglobin, hyaluronic acid, plasma type IV collagen, and ferritin levels by a latex agglutination method. Commercial enzyme-linked immunosorbent assay kits were used to measure serum levels of total adiponectin (Sekisui Medical Co., Ltd., Tokyo, Japan), tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, and leptin (R&D Systems Inc., Minneapolis, MN, USA), and thiobarbituric acid reactive substances (Cayman Chemical Co., Ann Arbor, MI, USA). Surrogate markers were calculated using the homeostasis model assessment of insulin resistance (HOMA-IR)[@b17-tcrm-11-371] and from NAFLD fibrosis scores.[@b18-tcrm-11-371]

Statistical analysis
--------------------

The statistical analysis was performed using Statistical Package for the Social Sciences version 20 software (SPSS Inc, Chicago, IL, USA). Descriptive parameters show the median (95% confidence interval) or proportion (%). Effects of training were evaluated by changes (baseline -- after 24 weeks) in the variable and were analyzed using the Wilcoxon signed-rank test.

Results
=======

Adherence to and adverse events of hybrid training program
----------------------------------------------------------

None of the patients developed any NAFLD-related complications during the study period, and all completed the study. During the HYB program, no severe adverse events developed, including electric stimulation-related burns or muscle strain, although muscle fatigue was seen in all patients. Based on the 3-day food records, the total estimated mean (± standard deviation) daily energy intake from baseline to week 24 was 1,513±151 kcal/day to 1,573±205 kcal/day.

Effects of hybrid training on body weight, skeletal muscle, and fat
-------------------------------------------------------------------

Body weight (−4.7%) and body fat (−3.8%) were significantly decreased after the HYB intervention ([Table 1](#t1-tcrm-11-371){ref-type="table"}). However, skeletal muscle (−1.9%) and waist circumference (−2.3%) were not significantly changed after the intervention ([Table 1](#t1-tcrm-11-371){ref-type="table"}).

Effects of hybrid training on muscle strength and muscle fat deposition
-----------------------------------------------------------------------

Although no significant changes in skeletal muscle mass were observed ([Figure 3A](#f3-tcrm-11-371){ref-type="fig"}), muscle strength of the quadriceps (+18.4%), but not that of the hamstrings (+12.5%), was significantly increased after the intervention, as shown in [Figure 3B](#f3-tcrm-11-371){ref-type="fig"}. On analysis by ^1^H nuclear magnetic resonance spectroscopy, levels of intramyocellular lipids (−15.5%) but not extramyocellular lipids (−7.3%) were decreased in the quadriceps after HYB ([Figure 4](#f4-tcrm-11-371){ref-type="fig"}).

Effects of hybrid training on liver steatosis
---------------------------------------------

Liver steatosis grade, determined by ultrasonography, was significantly decreased after HYB (−16.7%), as shown in [Table 2](#t2-tcrm-11-371){ref-type="table"}.

Effects of hybrid training on liver dysfunction
-----------------------------------------------

Liver function tests revealed significant improvements in serum AST (−18.4%), ALT (−35.8%), and γ-GT (−21.6%) levels after the HYB intervention ([Table 2](#t2-tcrm-11-371){ref-type="table"}).

Effects of hybrid training on lipid profile
-------------------------------------------

There was a significant decrease in serum free fatty acid levels (−4.9%) after the HYB intervention ([Table 2](#t2-tcrm-11-371){ref-type="table"}). However, other lipids, including high-density lipoprotein cholesterol (−2.8%), low-density lipoprotein cholesterol (−6.5%), and triglycerides (−6.4%), were not significantly different after the intervention ([Table 2](#t2-tcrm-11-371){ref-type="table"}).

Effects of hybrid training on insulin resistance
------------------------------------------------

Fasting plasma glucose (−0.8%) and HOMA-IR (−2.7%) were significantly decreased after the HYB intervention. However, fasting plasma insulin (−10.6%) and glycated hemoglobin (−3.1%) were not significantly decreased ([Table 2](#t2-tcrm-11-371){ref-type="table"}).

Effects of hybrid training on adipocytokine levels
--------------------------------------------------

The participants showed a significant reduction in serum leptin (−17.4%), TNF-α (−23.2%), and IL-6 (−30.5%) levels after the HYB intervention. However, adiponectin levels (+10.8%) were not significantly increased ([Figure 5](#f5-tcrm-11-371){ref-type="fig"}).

Effects of hybrid training on inflammatory, oxidative stress, and hepatic fibrosis markers
------------------------------------------------------------------------------------------

Inflammatory markers, the high-sensitivity C-reactive protein (−36.1%) and ferritin (−16.0%), and thiobarbituric acid reactive substances (−17.8%) as known oxidative stress marker levels were significantly decreased after the HYB intervention ([Table 2](#t2-tcrm-11-371){ref-type="table"}). Liver fibrosis markers, eg, hyaluronic acid (+35.3%) and type IV collagen (−12.8%) levels, and the NAFLD fibrosis score (−107.6%) were not significantly improved ([Table 2](#t2-tcrm-11-371){ref-type="table"}).

Discussion
==========

The present study shows that HYB in middle-aged obese women with NAFLD increased skeletal muscle strength in those parts of the body that received the training. Moreover, HYB decreased intramyocellular lipid concentrations, reduced body fat mass, and attenuated liver steatosis. It should be noted that HYB achieved a significantly greater degree of attenuation in the pathological indices of insulin resistance and liver dysfunction.

As with other types of resistance training, HYB was not found to be superior to the control condition in terms of improving body composition in obese women with NAFLD. The improvement effect of this training with regard to body fat mass is consistent with a previous report indicating low effectiveness of ordinary electrical muscle stimulation for decreasing body fat mass.[@b19-tcrm-11-371] However, the decrease in body fat mass observed after training is a factor that explains the significant decrease in blood leptin level. Leptin is an important factor promoting liver fibrosis in the pathogenesis of NAFLD.[@b20-tcrm-11-371]

One of the advantages of HYB is that it decreases blood liver enzyme (ALT, AST, and γ-GT) levels, thereby alleviating liver dysfunction and improving the condition of the liver in patients with NAFLD. However, our findings were inadequate to suggest that the change in body composition resulting from HYB was responsible for the attenuated liver dysfunction. The presence of factors such as insulin resistance[@b21-tcrm-11-371] and oxidative stress[@b22-tcrm-11-371],[@b23-tcrm-11-371] is important in the spread of hepatic lesions. The underlying mechanism of improvement in the state of the liver in patients with NAFLD who receive HYB may be assumed to involve attenuation of insulin resistance that is not mediated by a decrease in body weight, together with induction of molecular mechanisms involved in activation of the mechanism of endogenous response to oxidative stress.

The post-training attenuation of levels of ferritin, an inflammatory marker, the tendency toward attenuation in high-sensitivity C-reactive protein levels, and attenuation of serum levels of leptin, an adipokine, and of proinflammatory cytokines, eg, TNF-α and IL-6, suggest that the underlying mechanism of improvement of liver dysfunction brought about by HYB may involve attenuation of oxidative stress.

Another point of superiority of HYB with respect to skeletal muscle is that an increase in the strength of quadriceps femoris and a decrease in intramyocellular lipids were observed in the absence of an increase in skeletal muscle mass ([Figures 3](#f3-tcrm-11-371){ref-type="fig"} and [4](#f4-tcrm-11-371){ref-type="fig"}). In addition to intrahepatic fat content, fatty metamorphosis of skeletal muscle tissue has been shown to contribute independently to the onset of insulin resistance.[@b24-tcrm-11-371] The decrease in intramyocellular lipid levels resulting from HYB was considered to be related to attenuation of HOMA-IR. Moreover, the decreases in blood levels of free fatty acids, leptin, TNF-α, and IL-6 resulting from HYB were considered to be factors contributing to the attenuation of insulin resistance. Leptin acts via the sympathetic nervous system to induce lipolysis[@b25-tcrm-11-371] and known good predictors to detect the presence of liver steatosis.[@b26-tcrm-11-371] Improvement of liver dysfunction by HYB is considered to be the consequence of restoration of insulin sensitivity and reduction of abnormal fat accumulation in the liver via resolution of the adipokine imbalance ([Figure 6](#f6-tcrm-11-371){ref-type="fig"}).

Interestingly, "exercise factors" known as myokines[@b27-tcrm-11-371] may play a part in the improvement elicited by HYB in patients with NAFLD. Myokines are released by skeletal muscle cells during contraction and have endocrine activity. Research findings suggest that IL-6 is a molecule that triggers exercise-induced metabolic changes in the liver and adipose tissue.[@b28-tcrm-11-371] In addition, exercise has been reported to decrease IL-6 transcription in skeletal muscle.[@b29-tcrm-11-371] However, future study of the relationship between myokines and skeletal muscle training at a more detailed molecular level is needed.

The guidelines for management of nonalcoholic steatohepatitis/NAFLD published by the Japan Society of Hepatology[@b30-tcrm-11-371] discuss exercise therapy and describe methods similar to those recommended for obesity.[@b31-tcrm-11-371] Although not with specific reference to NAFLD, a minimum of 20 minutes of aerobic exercise a day is recommended. In the guidelines, anaerobic exercise (eg, short-range sprinting, weight lifting, and push-ups) is not recommended. Nevertheless, our results for HYB, albeit from a pilot trial, indicate that the effects of strength training as resistance exercise is of considerable significance because, although the effect in terms of weight reduction is small, metabolic function can be improved while maintaining skeletal muscle mass. As resistance exercise, HYB reduces ectopic steatosis in the liver and the skeletal muscles while attenuating insulin resistance, which is extremely useful in the management of patients with NAFLD.

In conclusion, the present study demonstrates that HYB for the lower extremities in middle-aged obese women with NAFLD exerts an antiobesity effect and attenuates liver dysfunction and insulin resistance in association with an increase in muscle strength and a decrease in ectopic muscle fat. Therefore, HYB has potential as a new type of exercise therapy for liver disease in patients with NAFLD.
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![Enrollment of study subjects.\
**Abbreviations:** ALT, alanine aminotransferase; NAFLD, nonalcoholic fatty liver disease.](tcrm-11-371Fig1){#f1-tcrm-11-371}

![Principle of hybrid training.\
**Notes:** During knee extension (**A**), the quadriceps are voluntarily contracted and the hamstrings are electrically stimulated at the same time. During knee flexion (**B**), the hamstrings are voluntarily contracted and the quadriceps are electrically stimulated at the same time.](tcrm-11-371Fig2){#f2-tcrm-11-371}

![Effects of the hybrid training on the muscle cross-sectional area (**A**), strength (**B**) of the femurs of middle-aged obese women with nonalcoholic fatty liver disease. \**P*\<0.05, significant difference between baseline and week 24.\
**Notes:** The lower edge, midline, and upper edge of each box represent the 25th percentile, median, and 75th percentile scores, respectively. The line from each box extends to the minimum and maximum score.\
**Abbreviation:** NS, not statistically significant.](tcrm-11-371Fig3){#f3-tcrm-11-371}

![Effects of hybrid training on muscle fat deposit in the femurs of middle-aged obese women with nonalcoholic fatty liver disease. \**P*\<0.05, significant difference between baseline and week 24.\
**Notes:** The lower edge, midline, and upper edge of each box represent the 25th percentile, median, and 75th percentile scores, respectively. The line from each box extends to the minimum and maximum score.\
**Abbreviations:** EMCL, extramyocellular lipids; IMCL, intramyocellular lipids; NS, not statistically significant.](tcrm-11-371Fig4){#f4-tcrm-11-371}

![Effects of hybrid training on serum levels of TNF-α, IL-6, leptin, and adiponectin in middle-aged obese women with nonalcoholic fatty liver disease. \**P*\<0.05, significant difference between baseline and week 24.\
**Notes:** The lower edge, midline, and upper edge of each box represent the 25th percentile, median, and 75th percentile scores, respectively. The line from each box extends to the minimum and maximum score.\
**Abbreviations:** IL-6, interleukin-6; NS, not statistically significant; TNF-α, tumor necrosis factor-alpha.](tcrm-11-371Fig5){#f5-tcrm-11-371}

![Schematic summary of the beneficial effects of the hybrid training in middle-aged obese women with NAFLD.\
**Abbreviations:** FPG, fasting plasma glucose; HOMA-IR, homeostasis model assessment of insulin resistance; IL-6, interleukin-6; IMCL, intramyocellular lipids; NAFLD, nonalcoholic fatty liver disease; TNF-α, tumor necrosis factor-alpha.](tcrm-11-371Fig6){#f6-tcrm-11-371}

###### 

Outcome for body weight and composition in 15 middle-aged obese women with nonalcoholic fatty liver disease who participated in a hybrid training program

  Parameters                            Hybrid training (n=15)   Change               
  ------------------------------------- ------------------------ -------------------- --------------------------------------------------
  Anthropometric and body composition                                                 
   Weight (kg)                          63.3 (57.7--71.8)        60.3 (58.6--70.4)    −3.0[\*](#tfn2-tcrm-11-371){ref-type="table-fn"}
   Skeletal muscle (kg)                 21.1 (19.8--21.9)        20.7 (19.8--21.4)    −0.4
   Body fat (kg)                        23.5 (20.6--31.0)        22.6 (20.5--31.3)    −0.9[\*](#tfn2-tcrm-11-371){ref-type="table-fn"}
   Waist circumference (cm)             91.3 (86.6--101.5)       89.2 (82.6--101.0)   −2.1

**Notes:** Values are presented as the group medians (95% confidence interval). The comparison of changes over time, from pre treatment to post treatment, for all dependent variables was analyzed by Wilcoxon's rank sum test.

*P*\<0.05, significant difference between baseline and week 24.

###### 

Outcomes for hepatic steatosis and blood testing in 15 middle-aged obese women with nonalcoholic fatty liver disease who participated in a hybrid training program

  Parameters                          Hybrid training (n=15)   Change                   
  ----------------------------------- ------------------------ ------------------------ ----------------------------------------------------
  Ultrasonography                                                                       
   Hepatic steatosis grade            3.0 (2.0--3.0)           2.5 (1.0--3.0)           −0.5[\*](#tfn4-tcrm-11-371){ref-type="table-fn"}
  Liver dysfunction                                                                     
   AST (U/L)                          38 (23--71)              31 (21--51)              −7[\*](#tfn4-tcrm-11-371){ref-type="table-fn"}
   ALT (U/L)                          53 (20--65)              34 (22--54)              −19[\*](#tfn4-tcrm-11-371){ref-type="table-fn"}
   γ-GT (U/L)                         37 (19--62)              29 (18--49)              −8[\*](#tfn4-tcrm-11-371){ref-type="table-fn"}
  Lipid profile                                                                         
   FFA (mEq/L)                        0.81 (0.63--1.01)        0.77 (0.50--0.91)        −0.04[\*](#tfn4-tcrm-11-371){ref-type="table-fn"}
   TG (mg/dL)                         110 (73--152)            103 (79--128)            −7
   HDL-C (mg/dL)                      54.4 (49.9--59.9)        52.9 (46.6--60.8)        −1.5
   LDL-C (mg/dL)                      124 (100--145)           116 (101--140)           −8
  Insulin resistance                                                                    
   FPG (mg/dL)                        123 (111--173)           122 (108--145)           −1[\*](#tfn4-tcrm-11-371){ref-type="table-fn"}
   FPI (μU/mL)                        11.3 (7.5--15.9)         10.1 (6.7--16.3)         −1.2
   HOMA-IR                            3.39 (2.26--6.04)        3.30 (1.77--5.27)        −0.09[\*](#tfn4-tcrm-11-371){ref-type="table-fn"}
   HbA~1c~ (%)                        6.4 (5.5--7.0)           6.2 (5.3--7.1)           −0.2
  Inflammatory and oxidative stress                                                     
   hs-CRP (mg/dL)                     0.097 (0.034--0.228)     0.062 (0.033--0.165)     −0.035[\*](#tfn4-tcrm-11-371){ref-type="table-fn"}
   Ferritin (ng/mL)                   125 (51--158)            105 (46--156)            −20[\*](#tfn4-tcrm-11-371){ref-type="table-fn"}
   TBARS (μM)                         19.7 (16.3--26.2)        16.2 (15.1--19.0)        −3.5[\*](#tfn4-tcrm-11-371){ref-type="table-fn"}
  Fibrosis markers                                                                      
   HA (ng/mL)                         51 (39--69)              69 (35--85)              +18
   Type IV (ng/mL)                    187 (130--216)           163 (133--202)           −24
   NAFLD fibrosis score               −0.157 (−0.941, 0.627)   −0.326 (−0.870, 0.219)   −0.169

**Notes:** Values are presented as the group medians (95% confidence interval). The comparison of changes over time, from pre treatment to post treatment, for all dependent variables was analyzed by Wilcoxon's rank sum test.

*P*\<0.05, significant difference between the baseline and the 24th week.

**Abbreviations:** AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GT, gamma-glutamyl transpeptidase; FFA, free fatty acid; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FPG, fasting plasma glucose; FPI, fasting plasma insulin; HbA~1c~, glycated hemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance; hs-CRP, high sensitivity C-reactive protein; TBARS, thiobarbituric acid reactive substances; HA, hyaluronic acid; NAFLD, nonalcoholic fatty liver disease; Type IV, type IV collagen.
